The present disclosure relates to amorphous and crystalline forms of (R)—N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoro-quinolin-4-yl)cyclohexyl)propanamide and its salts/cocrystals, solvates, and/or hydrates, processes for their production, pharmaceutical compositions comprising them, and methods of treatment using them.

There is disclosed a process for recovering monoethanolamine from an aqueous mother liquor solution comprising the steps of: (a) adding excess ammonia or alkali hydroxide and a solvent to the aqueous solution comprised of monoethanolamine sulfate and at least one component selected from the group of inorganic salts consisting of ammonium sulfate, ammonium sulfite, alkali sulfite, and alkali sulfate, to precipitate the inorganic salts, wherein the alkali is lithium, sodium, or potassium; (b) separating the inorganic salts by means of a solid-liquid separation to yield an aqueous solution comprised of the monoethanolamine; and (c) distilling the solvent to yield an aqueous solution comprised of the monoethanolamine and optionally purifying the MEA by distillation. The recovered MEA is recycled to produce taurine.

There is disclosed a process for recovering monoethanolamine from an aqueous mother liquor solution comprising the steps of: (a) adding excess ammonia or alkali hydroxide and a solvent to the aqueous solution comprised of monoethanolamine sulfate and at least one component selected from the group of inorganic salts consisting of ammonium sulfate, ammonium sulfite, alkali sulfite, and alkali sulfate, to precipitate the inorganic salts, wherein the alkali is lithium, sodium, or potassium; (b) separating the inorganic salts by means of a solid-liquid separation to yield an aqueous solution comprised of the monoethanolamine; and (c) distilling the solvent to yield an aqueous solution comprised of the monoethanolamine and optionally purifying the MEA by distillation. The recovered MEA is recycled to produce taurine.

A sulfonic acid derivative, wherein the sulfonic acid derivative is represented by the following general formula (1):

R.sup.1COOCH.sub.2CH.sub.2CFHCF.sub.2SO.sub.3.sup.−M.sup.+  (1)

where: R.sup.1 represents a monovalent organic group having carbon number of 1 to 200, having at least one hydroxyl group and optionally having a substituent other than the hydroxyl group; and M.sup.+ represents a counter cation.

Provided are a hydroxyethyl sulfonate of a cyclin-dependent protein kinase inhibitor, a crystalline form thereof and a preparation method therefor. Specifically, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperidin-4-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one hydroxyethyl sulfonate (compound of formula (I)), a crystal form I thereof and a preparation method therefor are provided. Crystal form I of the compound of formula (I) has good chemical and crystalline stability, low toxicity, and low residual crystallization solvent. Therefore, the crystal form I can be used in improved clinical therapy.

##STR00001##

Provided are a hydroxyethyl sulfonate of a cyclin-dependent protein kinase inhibitor, a crystalline form thereof and a preparation method therefor. Specifically, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperidin-4-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one hydroxyethyl sulfonate (compound of formula (I)), a crystal form I thereof and a preparation method therefor are provided. Crystal form I of the compound of formula (I) has good chemical and crystalline stability, low toxicity, and low residual crystallization solvent. Therefore, the crystal form I can be used in improved clinical therapy.

##STR00001##

A three fused ring derivative-containing salt and a crystal form thereof. In particular, the present invention relates to a compound having general formula (I), a crystal form thereof, a preparation method therefor, a pharmaceutical composition containing a therapeutically effective amount of the compound and the crystal form thereof, and use thereof in the preparation of a medicament for treating PI3K-mediated related diseases.

##STR00001##

The present invention relates to novel uses of stable inorganic peroxoacids as catalysts in the preparation of alkanesulfonic acids from alkanes and sulfur trioxide, methods for the production of alkanesulfonic acids employing said catalysts as well as reaction mixtures comprising said catalysts. The invention particularly relates to the production of methanesulfonic acid from methane and sulfur trioxide employing stable inorganic peroxoacids as catalysts.

The present invention relates to novel uses of stable inorganic peroxoacids as catalysts in the preparation of alkanesulfonic acids from alkanes and sulfur trioxide, methods for the production of alkanesulfonic acids employing said catalysts as well as reaction mixtures comprising said catalysts. The invention particularly relates to the production of methanesulfonic acid from methane and sulfur trioxide employing stable inorganic peroxoacids as catalysts.

The present invention relates to novel uses of stable inorganic peroxoacids as catalysts in the preparation of alkanesulfonic acids from alkanes and sulfur trioxide, methods for the production of alkanesulfonic acids employing said catalysts as well as reaction mixtures comprising said catalysts. The invention particularly relates to the production of methanesulfonic acid from methane and sulfur trioxide employing stable inorganic peroxoacids as catalysts.